CARD11, which is associated with lack of response to ibrutinib,17 encodes a scaffold protein required for BCR activation of NF‐κB signaling and implicated in lymphoma tumorigenesis,46 indicating that resistance to ibrutinib may be more closely linked to NF‐kB‐related pathways in the tumor. This evidence concerns the gene NFKB1 and lymphoma.